A clinical research of Xuebijing for treatment of blood capillary leak syndrome / 中国中西医结合急救杂志

ABSTRACT

Objective To explore the safety and therapeutic effect of Xuebijing injection for treatment of patients with capillary leak syndrome (CLS).Methods Seventy-seven patients with clinical diagnosis of CLS admitted to Intensive Care Unit (ICU) of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine (TCM) from November 2015 to October 2016 were enrolled, they were divided into a control group (35 cases) and a Xuebijing group (42 cases) according to random number table method. The conventional treatment was given and at the same time the primary disease was actively treated in the control group; while in the Xuebijing group, on the basic treatment of the control group, additionally, Xuebijing injection 100 mL+ 0.9% normal saline (100 mL) was intravenously dripped, twice a day, 5 days constituting one therapeutic course. Before and after treatment for 5 days, the white blood cell count (WBC), neutrophils percentage (N), alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), serum creatinine (SCr), procalcitonin (PCT), pH value, partial pressure of blood oxygen (PaO2), blood lactic acid value (Lac), activated partial thromboplastin time (APTT), prothrombin time (PT), blood platelet count (PLT) in the patients of the two groups were compared; and the acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ) score was recorded; the length of stay in ICU, mechanical ventilation time, and 28-day survival rate were statistically calculated in two groups.Results After treatment, the levels of WBC, N, PCT, ALT, AST, BUN, SCr, Lac, APACHE Ⅱ score in Xuebijing group were lower than those in the control group [WBC(×109/L) 9.85±0.61 vs. 13.87±2.58, N 0.75±0.08 vs. 0.90±0.10, PCT (μg/L) 1.13±0.71 vs. 4.99±1.38, ALT (U/L) 79.56±30.85 vs. 84.21±27.32, AST (U/L) 91.98±38.10 vs. 110.28±35.79, BUN (mmol/L) 7.35±0.82 vs. 8.57±1.43, SCr (μmol/L) 111.67±43.96 vs. 132.51±55.10, Lac (mmol/L) 1.88±1.01 vs. 3.31±1.46, APACHE Ⅱ score 11.34±3.59 vs. 17.65±4.77]; the PaO2, PLT, 28-day survival rate in Xuebijing group were higher than those in the control group [PaO2 (mmHg, 1 mmHg = 0.133 kPa) 75.47±21.10 vs. 54.22±15.23, PLT (×109/L) 211.54±58.25 vs. 153.27±49.69, 28-day survival rate 85.71% (36/42) vs. 71.43% (25/35), allP < 0.05]; the PT, APTT, ICU hospitalization time and mechanical ventilation time in Xuebijing group were shorter than those in the control group [PT (s) 13.62±2.11 vs. 18.45±4.26, APTT (s) 31.33±4.27 vs. 36.85±5.56, length of stay in ICU (days) 12.4±3.7 vs. 20.5±4.1, mechanical ventilation time (days) 10.5±4.9 vs. 18.7±5.5, allP < 0.05].Conclusion The application of Xuebijing injection for treatment of patients with CLS can relieve their disease situation, reduce inflammatory indicators, improve the blood coagulation function and hypoxemia, shorten the ICU hospitalization time and mechanical ventilation time, elevate the 28-day survival rate, and has no harmful effects on liver and kidney functions.